https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/gosh-researchers-receive-ucl-business-award/
GOSH researchers receive UCL Business Award
23 Jun 2017, 12:57 p.m.
Professors Bobby Gasper and Adrian Thrasher, both members of the BRC senior management team, have been awarded the UCL Business Award, in recognition of their work on the spin-out company Orchard Therapeutics.
Orchard is a biotechnology company focused on the development and commercialization of gene therapy medicines for children with rare diseases. It was launched in May 2016 with support from UCL Business and a £21 million investment from F-Prime Capital Partners.
Orchard focusses on restoring normal gene function in immunodeficiencies, metabolic diseases and haematological disorders and builds on GOSH researchers' expertise in stem, cell and gene therapies. Read more.
Professor Gaspar is Deputy Director of the NIHR GOSH BRC and Professor Thrasher is BRC Theme Lead for Gene, Stem and Cellular Therapies.
Fourth Annual NIHR GOSH BRC Image Competition - A Moment of Discovery
The Research and Innovation Communications team at GOSH and the NIHR GOSH Biomedical Research team invite you to enter our Research and Innovation Showcase: A Moment of Discovery.
New hope to prevent blindness in children with rare genetic disease
A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by Clinicians at GOSH and University College London Great Ormond Street Institute of Child Health (UCL GOS ICH).
GOSH only hospital outside of North America to receive innovation funding award for AI
GOSH has been awarded the Amazon Web Services IMAGINE Grant: Children’s Health Innovation Award, to support artificial intelligence (AI) development and drive progress for children’s healthcare.
New clinical trial at GOSH gives hope to children with aggressive blood cancer
Researchers at GOSH and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) are collaborating on a novel approach to clinical trials to give hope to children with an aggressive type of blood cancer, T-cell acute lymphoblastic leukaemia (T-ALL)